NOF TO PARTICIPATE IN ISCT 2024
NOF TO PARTICIPATE IN ISCT 2024
Vancouver, Canada 2024 (May 28 - June 1)
05/24/2024 by NOF EUROPE GmbH
NOF CORPORATION is pleased to announce its participation in the upcoming International Society for Cell & Gene Therapy Annual Meeting 2024 (ISCT 2024), which will be held at Vancouver Convention Centre, West Building, Vancouver, Canada from May 28th to June 1st.
The Conference website: https://www.isctglobal.org/isc...
As part of the event, NOF CORPORATION will showcase its products for at Drug Delivery System at Booth #410 from May 29th to 31st.
Additionally, Syed Reza, Drug Delivery Consultant at NOF CORPORATION, will give a poster presentation on the following topic on May 29th in POSTER NETWORKING RECEPTION 1.
Poster Presentation
Title:
High-Yield Primary T Cell Transfection with Biodegradable Lipid Nanoparticles
Date & Time:
May 29th / 19:00 – 20:30 PDT
Poster ID / Session:
#992 / IMMUNOTHERAPY - POSTER NETWORKING RECEPTION 1
Speaker:
Syed Reza, Drug Delivery Consultant at NOF CORPORATION
Abstract:
Effective gene-delivery systems for primary human T cell engineering are useful tools for both basic research and clinical immunotherapy applications. Pseudovirus-based systems and electro-transfection are the most popular strategies for genetic material transduction. Compared with viral-particle-mediated approaches, electro-transfection is safer, with a faster process time, and lower cost. However, this method is associated with low cell yields and is laborious due to multiple handling steps. Lipid nanoparticles (LNP) have emerged as a highly effective tool for nucleic acid delivery in vivo, yet have been difficult to demonstrate delivery to primary T-cells. Here we demonstrate the development of a novel LNP composed of biodegradable COATSOME® SS-Series that provide high level of gene transfection into human primary T-cells ex-vivo with a rapid single step transfection protocol. Compared to electroporation, the expression of an mRNA luciferase reporter was 13 fold higher in CD3+ activated human primary T-cells. The COATSOME® SS-Series were also evaluated in vivo with single doses up to 124 mg/kg being well tolerated in mice.
We also describe efforts to lower the cellular toxicity of ionizable lipids through improvements in biodegradable characteristics. Additional improvements in the design were undertaken to reduce the immunogenicity of ionizable lipids. Together these approaches can enable the accelerated development and manufacturing of cell therapies.
NOF CORPORATION invites attendees to visit booth #410 to explore our innovative drug delivery solutions and engage with their experts.
For further information or to arrange a meeting, please refer to the following contact information.